Skip to main content

Table 6 Efficacy or effectiveness of vaccination against human papillomavirus in males: infections in participants who were seronegative and PCR-negative at enrolment

From: Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review

Study

Design

No. of events/no. of participants

Unadjusted estimate (95% CI)

Confounder-adjusted estimate (95% CI)

VE (95% CI)

Vaccine

Control

Incident anogenital infection

HPV 16

  Giuliano et al. (2011) [32]a

RCT

62/2337.7 pyrs

103/2287.8 pyrs

NR

NA

41.1% (18.5–57.7%)

HPV 18

  Giuliano et al. (2011) [32]a

RCT

25/2441.3 pyrs

66/2440.6 pyrs

NR

NA

62.1% (39.2–77.1%)

Persisting anogenital infection

HPV 16

  Giuliano et al. (2011) [32]a

RCT

9/2382.4 pyrs

41/2312.9 pyrs

NR

NA

78.7% (55.5–90.9%)

HPV 18

  Giuliano et al. (2011) [32]a

RCT

1/2461.9 pyrs

25/2453.5 pyrs

NR

NA

96% (75.6–99.9%)

Incident anal infection

HPV 16

  Palefsky et al. (2011) [33]a

RCT

6/326 pyrs

25/322.8 pyrs

NR

NA

76.2% (40.7–92%)

HPV 18

  Palefsky et al. (2011) [33]a

RCT

0/346.3 pyrs

16/375.1 pyrs

NR

NA

100% (71.9–100%)

Persisting anal infection

HPV 16

  Palefsky et al. (2011) [33]a

RCT

1/331.5 pyrs

16/329.9 pyrs

NR

NA

93.8% (60.0–99.9%)

 HPV 18

  Palefsky et al. (2011) [33]a

RCT

0/346.3 pyrs

10/376.2 pyrs

NR

NA

100% (51.5–100%)

  1. NA not applicable, NR not reported, pyrs person-years, VE vaccine efficacy or effectiveness
  2. aVE as reported in the primary study